Table 2 Mean duration of health states for patients with wild-type KRAS tumours receiving panitumumab+BSC or BSC alone

From: A Q-TWiST analysis comparing panitumumab plus best supportive care (BSC) with BSC alone in patients with wild-type KRAS metastatic colorectal cancer

 

Mean duration (weeks)

  

Health state

Panitumumab+BSC ( n =124)

BSC alone ( n =119)

Difference (Panit+BSC) vs BSC

P >∣ Z ∣ a

TOX

3.47

1.09

2.37

0.0006

TWiST

13.26

8.01

5.25

<0.0001

REL

9.35

16.15

−6.80

<0.0001

  1. Abbreviations: BSC=best supportive care; Panit=panitumumab; REL=relapse period until death or end of follow-up; TOX=days with ⩾grade 3 adverse events; TWiST=time without symptoms or toxicity.
  2. aNull hypothesis: difference (panitumumab+BSC – BSC alone)=0.
Back to article page